Finding new targets for immunotherapy in Multiple Myeloma
Official title: Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10979960 · Data updated 2026-11-12
This study is looking for new ways to treat Multiple Myeloma by finding specific proteins on cancer cells that could help create better immunotherapies, with the hope of helping patients stay in remission longer after their current treatments.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $528,175 |
| NIH project number | 1R37CA276939-01A1 |
| Project ID | NIH-10979960 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with relapsed or refractory Multiple Myeloma who have previously undergone treatment.
✕Less likely to help
Patients with early-stage Multiple Myeloma or those who have not received prior treatments may not benefit from this research.
What this research studies
This research focuses on improving treatments for Multiple Myeloma, a type of blood cancer. The team is using advanced techniques like mass spectrometry and RNA sequencing to identify specific proteins on the surface of cancer cells that could be targeted by new immunotherapies. By analyzing samples from over 900 patients and various cancer cell lines, they aim to discover novel targets that could lead to more effective treatments. The goal is to enhance the duration of remission for patients who have already undergone other therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with Multiple Myeloma, potentially extending remission periods.
How similar studies have gone: Previous research has shown promise in targeting B-cell maturation antigen (BCMA) in Multiple Myeloma, indicating that exploring new targets could also yield successful outcomes.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Perna, Fabiana — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Perna, Fabiana
Related research
Other NIH-funded projects on the same topics.
-
3D tumor microenvironment platform to test immunotherapies for multiple myeloma
A 3D, lab-grown model of multiple myeloma’s tumor environment is being developed to help test immunotherapies and new drug options.
-
New targets on myeloma cells to drive smarter immunotherapies
Researchers are seeking new cell surface targets on myeloma cells to develop better immunotherapies for people with multiple myeloma who have exhausted other treatments.
-
3D lab platform that mimics the bone marrow around multiple myeloma for testing immunotherapies
A lab-grown 3D system that recreates the bone marrow environment so researchers can test immunotherapies and drugs for people with multiple myeloma.
-
Finding new targets on cancer cells for better multiple myeloma treatments
This research looks for new ways to target multiple myeloma cells to create more effective and lasting immune-based therapies for patients.
-
Analyzing the tumor environment in multiple myeloma to improve immunotherapy and drug testing.
This study is looking at how the environment around myeloma cells affects the cancer and its response to treatments, using a special 3D model to better understand why some patients do well with therapies like CAR-T while others don’t.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.